Revolution Medicines, Inc. (RVMD) Misses Q3 EPS by 20c

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q3 EPS of ($1.61), $0.20 worse than the analyst estimate of ($1.41). Revenue for the quarter came in at $0 versus the consensus estimate of $1.95 million.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Kroger (KR) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY27 EPS Guidance
• Boeing wins $13.4 billion contract modification from US military